Compare BioNano Genomics Inc (BNGO) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Remitly Global Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Remitly Global Inc trades at $23.7 (market cap $4.95B). The key difference: Remitly Global Inc is far larger — about 375× BioNano Genomics Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | RELY | |
|---|---|---|
Market Cap | $13.20M | $4.95B |
Sector | Health | Technology |
52-Week High | $4.92 | $24.28 |
52-Week Low | $1.09 | $12.20 |
Enterprise Value | $15.81M | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
RELY trades at $23.68, down 0.38% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates accelerating revenue growth, reaching $1.64B in 2025 with net income turning positive at $67.93M. Recent expansion includes a UAE banking license and Canadian business launch, supporting the 92% analyst buy rating with a $26.75 consensus target.
Outlook remains positive with projected 2026 revenue of $1.7B and net income of $106M. Key opportunities include market share gains in the $800B remittance space, while risks involve competitive pressure from payment giants and execution challenges in international expansion. The stock offers growth potential but requires monitoring of profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
